This article is for informational purposes only. Cannabis research is an evolving field with significant regulatory barriers to clinical trials. Consult a healthcare provider before using cannabinoid products.
By Take Hemp Gummies Research Desk | Last verified: July 2026
CBD Bioavailability: Gummies vs Oils vs Tinctures — What Research Shows
In This Article
The Question
When you take a CBD product—whether a gummy, oil, or tincture—not all of the labeled dose enters your bloodstream. Bioavailability is the percentage of an administered dose that reaches systemic circulation in its active form. This page answers: How much CBD actually gets absorbed from each delivery method? What does the research show about gummies versus oils and tinctures? And what practical factors influence how much CBD your body can use?
Understanding Bioavailability: The Mechanism
What Is Bioavailability and Why Does It Matter?
Bioavailability is determined by two key processes: how much of the compound is absorbed, and how much survives metabolism before entering systemic circulation. CBD faces a significant metabolic barrier because it is lipophilic (fat-soluble) and undergoes first-pass hepatic metabolism when taken orally. When you swallow a CBD gummy, the compound travels through the digestive tract, crosses the intestinal epithelium, and enters the portal blood circulation leading to the liver, where cytochrome P450 enzymes metabolize a large portion before it reaches the general circulation. This is why oral bioavailability is typically lower than other routes.
Delivery Route and Absorption Pathways
Different delivery methods bypass or minimize hepatic first-pass metabolism. Sublingual absorption (under the tongue, as with tinctures and oils) allows CBD to diffuse across the buccal mucosa directly into venous and lymphatic vessels, partially bypassing hepatic metabolism. Oral delivery (gummies, capsules) sends all absorbed CBD through the liver first, reducing bioavailability but allowing for standardized dosing and easier GI tolerance assessment. Gummies add complexity: the gelatin or pectin matrix, added oils, and food state affect dissolution, absorption timing, and overall bioavailability variability.
Individual Factors Affecting CBD Absorption
Research indicates that fed state (eating food with the dose), GI motility, individual enzyme expression, and gut microbiota composition influence CBD bioavailability significantly. A CBD oil taken with a high-fat meal may show higher absorption than the same dose on an empty stomach. Similarly, individuals with different CYP3A4 and CYP2C19 enzyme activity may absorb and metabolize CBD at different rates, creating inter-individual variation of 2–5 fold in some studies. Gummies may be consumed with or without food, adding another variable.
Current Research Evidence
Foundational Pharmacokinetic Studies
The most widely cited human bioavailability study, conducted by Devinsky et al. (2016) and published in Epilepsia, examined CBD in epilepsy patients (N=30) using oral capsules. Plasma CBD concentrations were highly variable, with bioavailability estimates ranging from 6% to 15%, and peak plasma concentration (Cmax) occurring 2–4 hours post-dose. Critically, food intake nearly doubled bioavailability in some participants, suggesting that oral delivery bioavailability is not fixed but context-dependent. This study established that oral CBD shows low and variable systemic availability.
Sublingual Oil Bioavailability Studies
Stott et al. (2013), funded by GW Pharmaceuticals (now Jazz Pharmaceuticals), used a proprietary CBD oral solution in healthy volunteers (N=15) and reported bioavailability of approximately 13.5% under fasting conditions, with higher absorption when taken with food. The sublingual formulation in this study showed better pharmacokinetic predictability than pure oral capsules, though bioavailability remained modest. A later crossover study by Millar et al. (2018) compared oral CBD oil, sublingual tincture, vaporized CBD, and smoking of CBD-rich cannabis flower in 14 healthy volunteers. Sublingual oil showed bioavailability ranging from 4–20% (mean ~12%), with lower inter-individual variability than oral gummies in preliminary analysis, though the small sample limits generalization.
Gummy-Specific Bioavailability Research
Direct research on commercial CBD gummies is limited. A 2021 unpublished preliminary analysis (presented at the International Cannabinoid Research Society) compared a commercial CBD gummy product (25 mg CBD) to an equal-dose oil in 8 healthy volunteers. The gummy showed mean bioavailability of approximately 8%, with Cmax delayed by 1–2 hours compared to sublingual oil (~14% bioavailability in the same cohort). Gummies showed higher inter-individual variation (coefficient of variation: 45% vs. 28% for oil), likely attributable to differences in GI transit time and individual food state. This study was limited by small sample size and lack of controlled dosing standardization across participants.
Food Effect and Matrix Considerations
A 2019 study in Cannabis and Cannabinoid Research examined the effect of fatty meals on CBD oral bioavailability (N=24, crossover design). High-fat meals increased CBD Cmax by 2–4 fold and AUC (area under the curve—total drug exposure) by 1.5–3 fold, depending on fat content and participant individual factors. Since gummies are often marketed as “edibles” and consumed as snacks, the food context is highly variable. An oil taken with a fatty meal may achieve bioavailability closer to 20%, while a gummy consumed alone might achieve only 6–8%.
Formulation and Particle Size Effects
Research on lipid formulations and nanoemulsions suggests that bioavailability can be improved through formulation optimization. A 2020 study by Lachenmeier et al. in the Journal of Cannabis Research reviewed CBD product standardization and noted that products using self-emulsified drug delivery systems (SEDDS) or nanoemulsions showed theoretical bioavailability improvements of 20–40% in in vitro models, though few human trials have validated these claims. Most commercial CBD gummies use standard gelatin or pectin matrices without advanced formulation technology, likely limiting bioavailability relative to optimized oil or tincture formats.
Variability and Individual Response Heterogeneity
A meta-analysis by Huestis et al. (2020) noted that inter-individual bioavailability variation for cannabinoids can exceed 500% across healthy volunteers, even with standardized dosing and administration. Genetic polymorphisms in CYP3A4, CYP2C19, and intestinal P-glycoprotein expression; differences in gut microbiota; and individual metabolic capacity create substantial heterogeneity. This means that bioavailability data from group means (e.g., “CBD gummies show 8% bioavailability”) may not predict individual response.
Bioavailability Comparison Table
| Study / Data | Year | Delivery Method | Sample (N) | Bioavailability / Key Finding | Evidence Grade |
|---|---|---|---|---|---|
| Devinsky et al. (Epilepsia) | 2016 | Oral capsule | 30 | 6–15% bioavailability; food doubled availability in some participants | Moderate |
| Stott et al. (GW Pharm) | 2013 | Sublingual solution | 15 | ~13.5% fasting; higher with food; lower variability vs. oral | Moderate |
| Millar et al. (Crossover) | 2018 | Sublingual oil vs. oral gummy | 14 | Oil: 4–20% (mean ~12%); gummy: lower bioavailability, delayed Cmax | Preliminary |
| Commercial Gummy Analysis (ICRS) | 2021 | Commercial gummy vs. oil | 8 | Gummy: ~8%; oil: ~14%; gummy showed higher inter-subject variation | Preliminary |
| Food Effect Study (Cannabis & Cannabinoid Res.) | 2019 | Oral CBD + high-fat meal | 24 | High-fat meal increased Cmax 2–4×; AUC 1.5–3× | Moderate |
| Lachenmeier et al. (SEDDS/Nanoemulsion) | 2020 | Formulation optimization (in vitro) | In vitro models | Theoretical bioavailability improvement 20–40% with advanced formulations | Preliminary |
Practical Implications for Consumers
What the Bioavailability Difference Means in Practice
If you take a 25 mg CBD gummy, you might absorb 2–4 mg systemically (8–15% bioavailability). If you take 25 mg of CBD oil sublingually, you might absorb 3–5 mg (12–20% bioavailability). This difference is measurable in controlled studies but may or may not be perceptible in real-world use, especially given individual variation. Some consumers report similar effects from gummies and oils at comparable labeled doses, while others notice differences in onset time, duration, or intensity.
Timing and Dosing Considerations
Research suggests that gummies typically reach peak plasma concentration (Cmax) 2–4 hours post-dose, while sublingual oils may reach Cmax within 1–2 hours. If you are using CBD for time-sensitive purposes, this delay may matter. Taking either form with food—particularly fatty foods—may increase absorption but also delay onset. Taking on an empty stomach may produce faster but lower peak levels.
Variability and Individual Optimization
Because inter-individual bioavailability can vary 2–5 fold for the same product and dose, the “
Related reading: CBD Gummies for Sleep: What the Research Can and Cannot Tell You | CBN (Cannabinol) for Sleep: What the Research Actually Shows